KRAS ((G12C) 抑制に対する耐性に関連した様々な変化
PubMedで要約を見る
まとめ
この要約は機械生成です。肺がんにおける KRAS (G12C) 阻害剤に対する耐性は,新しい KRAS,NRAS,または BRAF 変異によって発生することがあります. ERKシグナリングをターゲットにすることで,この既得抵抗性を克服し,患者の改善のために組み合わせ治療を提案することができます.
科学分野
- 腫瘍学
- 分子生物学
- 遺伝学
背景
- KRAS (G12C) 阻害剤は肺がんに適度な有効性を示しているが,耐性メカニズムは不明である.
- 耐性を理解することは 標的型療法による患者の治療結果を改善するために不可欠です
研究 の 目的
- 肺がん患者のKRAS (G12C) 阻害剤に対する遺伝的基礎を調査する.
- KRAS (G12C) 標的治療に対する抵抗を克服するための潜在的な戦略を特定する.
主な方法
- ソトラジブで治療された43人の患者の治療前と治療後の腫瘍サンプルを分析した.
- 患者に由来する異種移植と細胞系モデルを臨床前耐性研究に使用した.
- 細胞レベルでの抵抗メカニズムを分析するために単細胞配列を解析した.
主要な成果
- KRAS,NRAS,BRAF,その他の遺伝子の治療による変異は27人の患者で確認された.
- 前臨床モデルでは,二次RASおよび/ またはBRAF変異と関連した耐性があり,KRAS (G12C) 阻害を回避した.
- 耐性モデルにおけるERKシグナリング中間物質の共同標的化により,抗拡散効果が強化された.
結論
- KRAS (G12C) 阻害剤に対する獲得抵抗は,二次RAS/ BRAF変異を含む様々な遺伝的変異によって引き起こされる.
- ERKシグナリングをターゲットとする組み合わせ戦略は,得られた抵抗を克服することができます.
- より広範な患者集団でこれらの発見を評価するために,さらなる臨床試験が必要である.
関連する概念動画
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Guanine nucleotide exchange factors or GEF,
GTPase-activating proteins or GAPs, and
Guanine nucleotide-dissociation inhibitors or GDIs.
The GEF activates the GTPase by exchanging the bound-GDP with GTP. The...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

